Bioventus Inc. Stock Price, News & Analysis

Bioventus (BVS) announced it will release its fiscal Q2 2021 results after market close on August 10, 2021. Management will conduct a conference call at 5:00 PM ET the same day to discuss these results and provide a business update. Interested parties can join the call by dialing the provided numbers. A webcast will also be available on the company’s investor relations website, which will be archived for replay until August 10, 2022. The company focuses on delivering clinically proven products for active healing.

Bioventus Inc. (Nasdaq: BVS) announced that its human placental tissue product, PTP-001, significantly reduced pain and cartilage degeneration in a rat osteoarthritis model during a six-week study. Findings published in Osteoarthritis and Cartilage revealed that PTP-001's efficacy matched corticosteroid treatment. The company sees PTP-001 as a promising candidate for managing osteoarthritis symptoms and potentially modifying the disease. Further research and development plans are in place for PTP-001, aimed at addressing unmet clinical needs.

Bioventus (Nasdaq: BVS) announced its participation in two upcoming virtual conferences: the Canaccord Genuity Virtual Musculoskeletal Conference on May 20 at 8:30 a.m. ET and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9 at 11:20 a.m. ET. Presentation materials will be accessible on the investor relations section of the Bioventus website prior to each event. A live audio webcast and replay links will also be available for 30 days afterward. Bioventus focuses on innovations for active healing, particularly in osteoarthritis and various pain management solutions.

Bioventus Inc. (Nasdaq: BVS) reported its financial results for Q1 2021, revealing net sales of $81.8 million, a 4.0% year-over-year increase. Net income soared to $24.5 million, up 133.9% from last year. However, Adjusted EBITDA fell to $11.1 million, a decline of 22.3%. The company completed its acquisition of Bioness, enhancing its market reach in the neuromodulation sector. Bioventus raised its 2021 revenue guidance by $4 million to a new range of $406 million, anticipating a year-over-year increase of 23% to 26%.

Bioventus Inc. (Nasdaq: BVS) announced the commercial launch of the Bioness Integrated Therapy System (BITS) for Balance, marking significant advancements in rehabilitation technology. The system includes over 40 new programs, enhancing the platform's ability to assist healthcare providers in assessing and tracking patients' balance and strength. This initiative aligns with the increasing global need for rehabilitation services, as highlighted by recent studies indicating a substantial portion of the population could benefit from such therapies.

Bioventus (BVS) announced that it will release its first quarter fiscal year 2021 financial results after market close on May 12, 2021. A conference call to discuss the results will follow at 5:00 p.m. ET on the same day. Shareholders and interested parties can participate by dialing 844-945-2085 or accessing the live webcast via the company's investor relations website. Bioventus continues to focus on providing innovative and clinically proven solutions for active healing, including recent expansions through the acquisition of Bioness, enhancing its product portfolio for pain management and rehabilitation.

Bioventus (Nasdaq: BVS) has acquired Bioness for $45 million upfront, with potential additional payments up to $65 million based on performance milestones. Bioness, known for its neuromodulation and rehabilitation technologies, will enhance Bioventus’ portfolio and is expected to contribute positively to revenue and net income post-acquisition. The move aligns with Bioventus' strategy to leverage its existing infrastructure for growth, targeting a market worth over $8 billion. In 2020, Bioness reported $40 million in revenue.

Bioventus reported its financial results for Q4 and FY 2020, revealing a 1% increase in net sales to $98.6 million, with U.S. sales up 3%. However, international sales fell 17%. The full year saw a 6% decline in net sales to $321.2 million. Net income from continuing operations in Q4 was $2.3 million, down 58% year-over-year, while full-year net income rose 81% to $14.7 million. The company expects sales growth of 12% to 16% in 2021 and has raised $111.2 million from its IPO.

Bioventus (BVS) has initiated a Phase 1 open-label, dose-escalation study of MOTYS (PTP-001) for treating knee osteoarthritis (OA). The study, led by Dr. Shailesh Patel, has enrolled 20 patients receiving a single injection of PTP-001, with follow-ups to assess safety, efficacy, pain, and mobility improvements. This trial is pivotal amidst COVID-19 challenges and aims to expand treatment options beyond current corticosteroids and hyaluronic acid therapies. Bioventus targets a growing OA market with over 14 million affected individuals in the U.S.